View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Market Data
February 18, 2022

Coronary Artery Disease (CAD) (Ischemic Heart Disease) accounts for 12.2% share of global Cardiovascular clinical trial activity in 2021

By Carmen

Coronary Artery Disease (CAD) (Ischemic Heart Disease) accounted for a 12.2% share of the global clinical trials within the Cardiovascular therapy area in 2021, registering a decrease of 2.3% when compared with the last ten-year average of 14.5% share, according to GlobalData.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Non-industry sponsored trials outnumber industry sponsored trials for Coronary Artery Disease

Industry sponsored trials held a 37.6% share of all the clinical trials for Coronary Artery Disease indication in 2021, registering an increase of 6.3% when compared with the ten-year average of 31.3%. Non-industry sponsored trials accounted for a 62.4% share in 2021, marking a decrease of 6.3% over the ten-year average of 68.7%.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Top regions of industry sponsored Coronary Artery Disease trials

Asia-Pacific was the top region for industry sponsored Coronary Artery Disease trials, accounting for a 55.2% share in 2021, when compared with the five-year average of 68.3% and ten-year average of 54.6%.

Europe was at the second position with a 29.9% share in 2021, over the five-year average of 30.9% and ten-year average of 40.7%, followed by Middle East and Africa with a 9.2% share in 2021, as against five-year and ten-year averages of 4.4% and 7.6% respectively.

North America stood fourth with a 6.9% share in 2021, compared with the five-year average of 13.5% and ten-year average of 22.0%, followed by South and Central America with a 0.0% share in 2021, over five-year and ten-year averages of 5.6% and 7.8% respectively.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

China was the top country for industry sponsored Coronary Artery Disease trials, accounting for a 35.6% share in 2021, as against the five-year average of 40.9% and ten-year average of 26.8%.

Russia held an 18.4% share in 2021, over the five-year average of 12.5% and ten-year average of 17.4%, followed by Iran with a 9.2% share in 2021, compared with the five-year and ten-year averages of 1.2% and 0.9% respectively.

The US held a 6.9% share in 2021, as against the five-year average of 12.9% and ten-year average of 20.4%.

Thailand held a 5.7% share in 2021, over the five-year and ten-year averages of 7.1% and 4.6% respectively.

Top regions of non-industry sponsored Coronary Artery Disease trials

Asia-Pacific was the top region for non-industry sponsored Coronary Artery Disease trials, accounting for a 65.9% share in 2021 when compared with the five-year average of 54.7% and ten-year average of 50.4%.

Europe was at the second position with an 18.1% share in 2021, over the five-year and ten-year averages of 20.0% and 25.2% respectively, followed by North America with a 7.2% share in 2021, as against the five-year average of 9.7% and ten-year average of 12.4%.

Middle East and Africa stood at the fourth position with a 6.5% share in 2021, compared with the five-year average of 14.8% and ten-year average of 13.1%, followed by South and Central America with a 2.9% share in 2021, over the five-year and ten-year averages of 2.8% and 2.5% respectively.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

China was the top country for non-industry sponsored Coronary Artery Disease trials, accounting for a 41.3% share in 2021, as against the five-year average of 32.0% and ten-year average of 24.5%.

South Korea held an 8.7% share in 2021, over the five-year average of 7.9% and ten-year average of 8.4%, followed by Iran with a 5.1% share, compared with the five-year and ten-year averages of 12.8% and 10.5% respectively.

The US held a 4.3% share in 2021, as against the five-year average of 8.1% and ten-year average of 10.1%.

Australia held a 3.6% share in 2021, over the five-year average of 2.0% and ten-year average of 2.1%.

Phase I trials lead industry sponsored clinical trials for Coronary Artery Disease in 2021

Phase I trials held a 54.3% share of industry sponsored clinical trials for Coronary Artery Disease in 2021, over the five-year average of 50.8% and ten-year average of 41.6%.

Phase II trials held a 21.7% share in 2021, as against the five-year average of 18.3% and ten-year average of 21.5%. Phase IV trials held an 18.5% share in 2021, compared with the five-year and ten-year averages of 23.1% and 23.8% respectively.

Phase III trials held a 5.4% share in 2021, over the five-year average of 7.8% and ten-year average of 13.1%.

Phase IV trials lead non-industry sponsored clinical trials for Coronary Artery Disease in 2021

Phase IV trials held a 47.1% share of non-industry sponsored clinical trials for Coronary Artery Disease in 2021, over the five-year average of 47.4% and ten-year average of 45.7%.

Phase II trials held a 23.5% share in 2021, as against the five-year average of 31.3% and ten-year average of 32.6%. Phase III trials held a 17.6% share, compared with the five-year and ten-year averages of 15.6% and 16.0% respectively.

Phase I trials held a 11.8% share in 2021, over the five-year average of 5.7% and ten-year average of 5.8%.

Methodology: The clinical trials data used for the analyses were extracted from the Clinical Trials Database of GlobalData’s Pharma Intelligence Center. Clinical Trials are sourced from numerous government, non-government and company clinical trial registries worldwide alongside clinical research publications, scientific conferences, company websites, SEC filings and more. The information is gathered by a combination of automation and secondary research to ensure accuracy and validity. A small number of Phase 0, Phase I/II, Phase II/III, and Phase III/IV trials were combined with Phase I, Phase II, Phase III, and Phase IV trials, respectively.

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena